Latest news with #neurologicaldisorders
Yahoo
3 hours ago
- Business
- Yahoo
Addex Convenes Annual General Meeting 2025
Geneva, Switzerland, June 3, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its 2025 Annual General Meeting will take place on Tuesday June 24, 2025, at 11:00 am CEST at the Campus Biotech, Chemin des Mines 9, 1202 Geneva (doors open at 10:30 am). Agenda 1. Approval of the Annual Report, the Annual Financial Statements and the Consolidated Financial Statements for the business year 20242. Consultative vote on the Compensation Report for the business year 20243. Appropriation of the results4. Discharge of the members of the Board of Directors and of the Executive Management5. Re-elections of the members of the Board of Directors and re-election of the Chairman of the Board of Directors5.1. Re-election of Vincent Lawton as member and Chairman of the Board of Directors5.2. Re-election of Raymond Hill as member of the Board of Directors5.3. Re-election of Timothy Dyer as member of the Board of Directors5.4. Re-election of Roger Mills as member of the Board of Directors5.5. Re-election of Jake Nunn as member of the Board of Directors5.6. Re-election of Isaac Manke as member of the Board of Directors6. Re-elections of the members of the Compensation Committee6.1. Re-election of Vincent Lawton as member of the Compensation Committee6.2. Re-election of Raymond Hill as member of the Compensation Committee7. Re-election of the Auditors8. Re-election of the Independent Voting Rights Representative9. Approval of the compensation of the members of the Board of Directors and of the Executive Management9.1. Compensation of the members of the Board of Directors 9.2. Compensation of the members of the Executive Management10. MiscellaneousThe full invitation to the AGM 2025 may be found in the General Meetings section of the Company's website here. About Addex: Addex is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex's partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies. Addex is advancing an independent GABAB PAM program for chronic cough. Addex also holds a 20% equity interest in a private spin out company, Neurosterix LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, mGlu7 NAM for mood disorders and mGlu2 NAM for mild neurocognitive disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol 'ADXN' on each exchange. For more information, visit Contacts: Tim DyerChief Executive OfficerTelephone: +41 22 884 15 55PR@ Mike SinclairPartner, Halsin Partners+44 (0)7968 022075msinclair@ Addex Forward Looking Statements:This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled 'Risk Factors' in Addex Therapeutics' Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking in to access your portfolio
Yahoo
4 hours ago
- Business
- Yahoo
Addex Convenes Annual General Meeting 2025
Geneva, Switzerland, June 3, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its 2025 Annual General Meeting will take place on Tuesday June 24, 2025, at 11:00 am CEST at the Campus Biotech, Chemin des Mines 9, 1202 Geneva (doors open at 10:30 am). Agenda 1. Approval of the Annual Report, the Annual Financial Statements and the Consolidated Financial Statements for the business year 20242. Consultative vote on the Compensation Report for the business year 20243. Appropriation of the results4. Discharge of the members of the Board of Directors and of the Executive Management5. Re-elections of the members of the Board of Directors and re-election of the Chairman of the Board of Directors5.1. Re-election of Vincent Lawton as member and Chairman of the Board of Directors5.2. Re-election of Raymond Hill as member of the Board of Directors5.3. Re-election of Timothy Dyer as member of the Board of Directors5.4. Re-election of Roger Mills as member of the Board of Directors5.5. Re-election of Jake Nunn as member of the Board of Directors5.6. Re-election of Isaac Manke as member of the Board of Directors6. Re-elections of the members of the Compensation Committee6.1. Re-election of Vincent Lawton as member of the Compensation Committee6.2. Re-election of Raymond Hill as member of the Compensation Committee7. Re-election of the Auditors8. Re-election of the Independent Voting Rights Representative9. Approval of the compensation of the members of the Board of Directors and of the Executive Management9.1. Compensation of the members of the Board of Directors 9.2. Compensation of the members of the Executive Management10. MiscellaneousThe full invitation to the AGM 2025 may be found in the General Meetings section of the Company's website here. About Addex: Addex is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex's partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies. Addex is advancing an independent GABAB PAM program for chronic cough. Addex also holds a 20% equity interest in a private spin out company, Neurosterix LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, mGlu7 NAM for mood disorders and mGlu2 NAM for mild neurocognitive disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol 'ADXN' on each exchange. For more information, visit Contacts: Tim DyerChief Executive OfficerTelephone: +41 22 884 15 55PR@ Mike SinclairPartner, Halsin Partners+44 (0)7968 022075msinclair@ Addex Forward Looking Statements:This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled 'Risk Factors' in Addex Therapeutics' Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements.
Globe and Mail
5 days ago
- Business
- Globe and Mail
Elon Musk's Neuralink Raises $600M in a Recent Funding Round
Elon Musk's brain-implant company, Neuralink, has raised $600 million in a recent funding round, which pushed its pre-money valuation to $9 billion, according to Semafor. This latest round follows a $280 million Series D raise in 2023, which was led by Peter Thiel's Founders Fund. The company was previously valued at $5 billion based on private stock trades and had been rumored in April to be seeking around $500 million in new funding. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Interestingly, Neuralink is developing a brain-computer interface that includes a rechargeable, skull-mounted wireless implant with electrode threads that connect directly to the brain. The device is designed to help people with neurological disorders, such as paralysis or ALS, to control computers and other devices using only their thoughts. Neuralink recently announced that its patient registry is now available globally and that the U.S. FDA has granted its device a 'breakthrough' designation. Indeed, the company made headlines earlier this year after its first human patient was able to use the implant to browse the internet, post on social media, play video games, and move a computer cursor with his mind. Elon Musk has said that the chip could one day help treat a wide range of conditions, such as obesity, autism, depression, and schizophrenia, and might even allow healthy individuals to use telepathy or surf the web directly with their brains. What Is the Prediction for Tesla Stock? When it comes to Elon Musk's companies, most of them are privately held. However, retail investors can invest in his most popular company, Tesla (TSLA). Turning to Wall Street, analysts have a Hold consensus rating on TSLA stock based on 16 Buys, 10 Holds, and 11 Sells assigned in the past three months, as indicated by the graphic below. Furthermore, the average TSLA price target of $282.70 per share implies 16.7% downside risk. See more TSLA analyst ratings Disclaimer & Disclosure Report an Issue
Trade Arabia
26-05-2025
- Health
- Trade Arabia
Riyadh hospital pioneers AI device implant for brain stimulation
King Faisal Specialist Hospital & Research Centre (KFSHRC) in Riyadh has successfully executed a groundbreaking procedure in the Middle East, implanting an advanced smart device within the brain to help manage chronic neurological disorders. This device monitors abnormal electrical activity and sends targeted electrical impulses to the affected regions, aiming to alleviate symptoms, decrease dependence on medication, and enhance patients' quality of life, independence, and health stability. This state-of-the-art innovation enables patients to better control neurological symptoms and potentially lower medication doses by as much as 50%, reducing side effects and improving daily activities- especially for those with Parkinson's disease, epilepsy, and movement disorders, said the centre. The device's built-in artificial intelligence rapidly analyses brain signals to detect abnormal activity patterns and responds by providing targeted electrical stimulation to restore neural balance. This allows for highly accurate, adaptive treatment that adjusts to the patient's condition in real time without requiring continuous manual intervention from healthcare professionals. While benefits start to appear within the first few weeks post-implantation, achieving optimal results requires a fine-tuning period of one to three months, during which electrical responses are calibrated according to real-time brain signals collected by the device, it said. The procedure utilises minimally invasive methods lasting only three to five hours, avoiding large surgical cuts. This approach lessens recovery time, minimises complications, and encourages a quicker return to everyday activities.
Asharq Al-Awsat
22-05-2025
- Health
- Asharq Al-Awsat
KFSHRC Implants Region's First Smart Brain Device to Improve Neurological Disease Management
The King Faisal Specialist Hospital and Research Center (KFSHRC) in Riyadh has performed a one of a kind procedure in the Middle East, implanting an innovative smart device inside the brain to improve control over chronic neurological disorders, according to a KFSHRC press release. The device detects abnormal electrical activity and delivers precise electrical impulses to affected areas—helping reduce symptoms, minimize reliance on medication, and improve patients' quality of life, autonomy, and health stability. This innovation empowers patients to better manage neurological symptoms and potentially reduce medication doses by up to 50%, alleviating side effects and enhancing daily life, particularly for individuals living with Parkinson's disease, epilepsy, and movement disorders, SPA reported. The device's built-in artificial intelligence instantly analyses brain signals to detect abnormal activity patterns and automatically responds by delivering targeted electrical stimulation to restore neural balance. This enables highly precise, adaptive treatment that adjusts to the patient's condition in real time—without the need for continuous manual intervention by a medical team. While the device begins to show benefits within the first few weeks after implantation, optimal outcomes require a fine-tuning period of one to three months, during which the electrical responses are calibrated based on real-time brain signals captured by the device. The procedure uses minimally invasive techniques that take only three to five hours, avoiding large surgical incisions. This reduces recovery time, minimizes complications, and supports a quicker return to normal daily life. "This achievement highlights KFSHRC's ongoing progress in harnessing artificial intelligence and medical innovation to deliver high-precision, specialized care, meeting patient needs while shaping an advanced therapeutic model for the region and beyond," the release read.
